Efficacy and Safety of QGE031 (Ligelizumab) in Patients With Peanut Allergy

NCT04984876 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

211

Enrollment

INDUSTRY

Sponsor class

Stopped Study terminated by sponsor

Conditions

Allergy, Peanut

Interventions

DRUG: ligelizumab
DRUG: Placebo

Sponsor

Novartis Pharmaceuticals